Related Experiment Video
Updated: Sep 20, 2025

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
Published on: December 15, 2011
The Outside-In Journey of Tissue Transglutaminase in Cancer
Livia Elena Sima1, Daniela Matei2,3,4, Salvatore Condello5,6
1Department of Molecular Cell Biology, Institute of Biochemistry of the Romanian Academy, 060031 Bucharest, Romania.
Abstract:
Tissue transglutaminase (TG2) is a member of the transglutaminase family that catalyzes Ca2+-dependent protein crosslinks and hydrolyzes guanosine 5'-triphosphate (GTP). The conformation and functions of TG2 are regulated by Ca2+ and GTP levels; the TG2 enzymatically active open conformation is modulated by high Ca2+ concentrations, while high intracellular GTP promotes the closed conformation, with inhibition of the TG-ase activity. TG2's unique characteristics and its ubiquitous distribution in the intracellular compartment, coupled with its secretion in the extracellular matrix, contribute to modulate the functions of the protein. Its aberrant expression has been observed in several cancer types where it was linked to metastatic progression, resistance to chemotherapy, stemness, and worse clinical outcomes. The N-terminal domain of TG2 binds to the 42 kDa gelatin-binding domain of fibronectin with high affinity, facilitating the formation of a complex with β-integrins, essential for cellular adhesion to the matrix. This mechanism allows TG2 to interact with key matrix proteins and to regulate epithelial to mesenchymal transition and stemness. Here, we highlight the current knowledge on TG2 involvement in cancer, focusing on its roles translating extracellular cues into activation of oncogenic programs. Improved understanding of these mechanisms could lead to new therapeutic strategies targeting this multi-functional protein.
Insights
Tissue transglutaminase (TG2) regulates cancer progression by linking extracellular signals to oncogenic pathways. Understanding TG2
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Tissue transglutaminase (TG2) is a Ca2+-dependent enzyme involved in protein crosslinking and GTP hydrolysis.
- TG2's conformation and activity are modulated by Ca2+ and GTP levels, influencing its cellular and extracellular functions.
- Aberrant TG2 expression correlates with cancer progression, metastasis, chemoresistance, stemness, and poor clinical outcomes.
Purpose of the Study:
- To review the current understanding of TG2's involvement in cancer.
- To elucidate TG2's mechanisms in translating extracellular cues into oncogenic programs.
- To highlight TG2 as a potential therapeutic target in cancer treatment.
Main Methods:
- Literature review of TG2's role in cancer.
- Analysis of TG2's interactions with fibronectin and beta-integrins.
- Examination of TG2's regulation of epithelial-to-mesenchymal transition and stemness.
Main Results:
- TG2 binds fibronectin and beta-integrins, mediating cell adhesion and matrix interactions.
- TG2 regulates epithelial-to-mesenchymal transition and stemness, contributing to cancer progression.
- TG2 translates extracellular signals into activation of oncogenic pathways.
Conclusions:
- TG2 plays a critical role in cancer development and progression.
- Targeting TG2 may offer novel therapeutic strategies for cancer treatment.
- Further research into TG2 mechanisms can improve cancer therapy.
Related Concept Videos
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...

